1. PD-L1 expression in tongue squamous cell carcinoma.
- Author
-
Akisada, Naoki, Nishimoto, Kohei, Takao, Soshi, Gion, Yuka, Marunaka, Hidenori, Tachibana, Tomoyasu, Makino, Takuma, Miki, Kentaro, Akagi, Yusuke, Tsumura, Munechika, Toji, Tomohiro, Yoshino, Tadashi, Nishizaki, Kazunori, Orita, Yorihisa, and Sato, Yasuharu more...
- Subjects
PROGRAMMED cell death 1 receptors ,SQUAMOUS cell carcinoma ,PROGRAMMED death-ligand 1 ,HEAD & neck cancer ,PROGRESSION-free survival ,CELL death ,HYPOGLOSSAL nerve - Abstract
Purpose: Immune checkpoint proteins programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) are important therapeutic targets for head and neck cancer. This large-scale case study aimed to analyze tongue squamous cell carcinomas (SCCs) and evaluate the correlation between PD-L1 expression and clinical prognosis. So far, this study is the largest case study on PD-L1 expression in tongue SCCs. Methods: This is a case–control study that analyzed 121 tongue SCCs. Paraffin-embedded sections and clinical data were obtained retrospectively and immunohistochemistry with PD-L1 was performed. Results: 11.6% contained ≥ 50% of PD-L1-positive cells, 57.1% of these cases had a poor prognosis with nodal metastasis. Among cases of T1/2 primary lesions with nodal metastasis, cases of high PD-L1 expression had a significantly shorter disease-free survival than cases of no PD-L1 expression (p = 0.018). The hazard ratio for high PD-L1 expression was 3.21 (95 per cent CI, 1.26–8.72) compared with no PD-L1 expression after adjusting for other factors. Conclusions: These data indicate that PD-L1 upregulation in tongue SCCs is associated with a more advanced stage and shorter disease-free survival. PD-1/PD-L1 inhibitors might hence constitute potential adjuvant therapy for tongue SCCs with PD-L1 upregulation. [ABSTRACT FROM AUTHOR] more...
- Published
- 2021
- Full Text
- View/download PDF